J Cancer 2022; 13(15):3652-3659. doi:10.7150/jca.78246 This issue Cite

Research Paper

miR-143 mediates abiraterone acetate resistance by regulating the JNK/Bcl-2 signaling pathway in prostate cancer

Yigeng Feng#, Hongwen Cao#, Wenyang Zhao#, Lei Chen, Dan Wang, Renjie Gao

Surgical Department I (Urology Department), LONGHUA Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road South, Xuhui District, Shanghai 200032, China
#These authors contributed equally to this work

Citation:
Feng Y, Cao H, Zhao W, Chen L, Wang D, Gao R. miR-143 mediates abiraterone acetate resistance by regulating the JNK/Bcl-2 signaling pathway in prostate cancer. J Cancer 2022; 13(15):3652-3659. doi:10.7150/jca.78246. https://www.jcancer.org/v13p3652.htm
Other styles

File import instruction

Abstract

Graphic abstract

Background: miR-143 is known to be downregulated in various cancer cells and tumors and generally plays a tumor-suppressor role. miR-143. However, the role of miR-143 in the mediation of the sensitivity of prostate cancer cells to abiraterone acetate remains unrevealed.

Methods: The expression levels of miRNAs were determined by miRNA microarray and quantitative real-time PCR (qRT-PCR). The protein levels were assessed by Western blot assay. Cell viability and apoptosis were respectively measured by Cell Counting Kit-8 (CCK-8) assay and flow cytometry.

Results: We identified that miR-143 was significantly downregulated in PC3-AbiR cells compared to PC3 cells. Overexpression of miR-143 promoted PC-AbiR sensitivity to abiraterone acetate in vitro and in vivo. We also revealed that miR-143 upregulation inhibited p-JNK (c-Jun N-terminal kinases) and increased p-Bcl2 (B-cell lymphoma 2), contributing to abiraterone acetate-induced apoptosis in PC3-AbiR cells. Finally, we showed that the combination of miR-143 and abiraterone acetate exerted the most profound tumor inhibition effect and prolonged the mice survival rate in PC3-AbiR tumor-bearing mice.

Conclusion: Upregulation of miR-143 may serve as a new strategy to enhance the therapeutical effect of abiraterone acetate on prostate cancer patients who are resistant to abiraterone acetate.

Keywords: miR-143, prostate cancer, abiraterone acetate, JNK/Bcl-2 signaling, drug resistance


Citation styles

APA
Feng, Y., Cao, H., Zhao, W., Chen, L., Wang, D., Gao, R. (2022). miR-143 mediates abiraterone acetate resistance by regulating the JNK/Bcl-2 signaling pathway in prostate cancer. Journal of Cancer, 13(15), 3652-3659. https://doi.org/10.7150/jca.78246.

ACS
Feng, Y.; Cao, H.; Zhao, W.; Chen, L.; Wang, D.; Gao, R. miR-143 mediates abiraterone acetate resistance by regulating the JNK/Bcl-2 signaling pathway in prostate cancer. J. Cancer 2022, 13 (15), 3652-3659. DOI: 10.7150/jca.78246.

NLM
Feng Y, Cao H, Zhao W, Chen L, Wang D, Gao R. miR-143 mediates abiraterone acetate resistance by regulating the JNK/Bcl-2 signaling pathway in prostate cancer. J Cancer 2022; 13(15):3652-3659. doi:10.7150/jca.78246. https://www.jcancer.org/v13p3652.htm

CSE
Feng Y, Cao H, Zhao W, Chen L, Wang D, Gao R. 2022. miR-143 mediates abiraterone acetate resistance by regulating the JNK/Bcl-2 signaling pathway in prostate cancer. J Cancer. 13(15):3652-3659.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.